For many years, aspirin has been one of the most common medicines used to protect people with heart disease from dangerous events such as heart attacks and strokes.
Doctors around the world have long recommended low-dose aspirin for people with coronary artery disease because it helps prevent blood clots from forming inside narrowed arteries.
But a major new study now suggests that another blood-thinning medicine, called clopidogrel, may actually work better than aspirin for long-term protection. The findings could eventually change the way millions of people with heart disease are treated.
The research was published in the medical journal The Lancet. Scientists analyzed information from nearly 29,000 patients who took part in seven different clinical trials.
After carefully reviewing the data, the researchers found that people taking clopidogrel had a lower risk of serious heart and stroke problems compared with those taking aspirin.
Coronary artery disease, often called CAD, is one of the leading causes of death around the world. The disease develops when fatty deposits build up inside the arteries that supply blood to the heart.
Over time, these arteries become narrow and stiff, reducing blood flow. If a blood clot suddenly blocks one of the arteries, it can trigger a heart attack. Reduced blood flow to the brain can also cause strokes.
Many people with CAD must take blood-thinning medicine for the rest of their lives to lower the risk of these dangerous events. Aspirin has been the standard treatment for decades because it is inexpensive, easy to obtain, and effective at reducing blood clotting.
However, aspirin is not perfect. Some people continue to have heart attacks or strokes even while taking it regularly. Aspirin can also irritate the stomach and increase the risk of bleeding in some patients. Because of these concerns, researchers have continued searching for other medicines that might work better.
Clopidogrel is another medicine that helps stop blood clots from forming. Doctors often prescribe it after certain heart procedures, such as placing stents inside blocked arteries, or after a heart attack.
In many cases, patients take clopidogrel together with aspirin for a short time after these procedures. But until recently, aspirin remained the most common medicine used for long-term treatment.
The new study suggests clopidogrel may provide stronger long-term protection. According to the analysis, people taking clopidogrel had a 14% lower risk of major cardiovascular events, including heart attacks and strokes, compared with those taking aspirin.
One of the most important findings involved safety. Because blood thinners reduce clotting, doctors always worry about the risk of serious bleeding.
Surprisingly, the study found that people taking clopidogrel did not experience more major bleeding than people taking aspirin. This means the medicine may offer better heart protection without increasing one of the biggest risks linked to blood-thinning drugs.
The study included many different groups of heart patients. Some participants had undergone procedures to place stents in their arteries, while others had experienced severe heart problems such as heart attacks. The researchers also examined whether genetic differences affected the results.
Some people carry genetic changes that may make clopidogrel less effective because their bodies cannot fully activate the medicine. Even in these patients, clopidogrel still appeared to provide benefits compared with aspirin.
This finding surprised researchers and suggests the medicine may work well across a broad range of patients.
Because both aspirin and clopidogrel are already widely available around the world, the findings could have a major impact on future medical guidelines. If future studies confirm the results, doctors may begin recommending clopidogrel more often as the main long-term treatment for people living with coronary artery disease.
The researchers say more work is still needed before treatment recommendations officially change.
Future studies will need to examine the long-term cost-effectiveness of clopidogrel and determine how well it performs in even larger and more diverse patient groups. Scientists also want to better understand which patients benefit the most.
Heart disease remains one of the world’s biggest health challenges. Millions of people live with coronary artery disease and rely on daily medicines to lower their risk of life-threatening complications. Even small improvements in treatment could help save many lives and reduce disability caused by heart attacks and strokes.
The study also highlights how medical science continues to evolve. Treatments that were once considered the best option can sometimes be replaced when better evidence becomes available.
Aspirin has played an important role in heart care for decades, but this new research suggests another common medicine may offer stronger protection for many patients.
Experts stress that patients should not stop or change their medications without speaking to their doctors. Blood-thinning medicines can be dangerous if used incorrectly, and the best treatment may vary depending on a person’s medical history and overall health.
Still, the findings give new hope that better long-term protection may soon be available for millions of people living with heart disease around the world.
If you care about heart health, please read studies about how vitamin D influences cholesterol levels, and what we know about egg intake and heart disease.
For more health information, please see recent studies about best supplements for heart disease prevention, and wild blueberries can benefit your heart and brain.
Copyright © 2026 Knowridge Science Report. All rights reserved.
